Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq staff had notified the company on April 14, 2025 that LNAI's common stock failed to maintain a $1.00 minimum bid over the prior 30 business days. Staff determined the closing bid price was at or above $1.00 for 11 consecutive business days from September 30, 2025 through October 14, 2025, restoring compliance and leaving the company eligible to remain listed on The Nasdaq Capital Market. Management said the milestone supports its focus on advancing an AI-powered platform for drug discovery and biodefense.
Lunai Bioworks (Nasdaq:LNAI) ha annunciato di aver riacquistato la conformità al requisito minimo di prezzo di offerta di Nasdaq secondo Listing Rule 5550(a)(2). Il personale di Nasdaq aveva informato l'azienda il 14 aprile 2025 che l'azione comune di LNAI non manteneva un prezzo minimo di $1,00 per i 30 giorni lavorativi precedenti. Il personale ha determinato che il prezzo di chiusura era pari o superiore a $1,00 per 11 giorni lavorativi consecutivi dal 30 settembre 2025 al 14 ottobre 2025, ripristinando la conformità e lasciando l'azienda idonea a rimanere quotata sul Nasdaq Capital Market. La direzione ha affermato che questo traguardo sostiene il suo obiettivo di avanzare una piattaforma basata sull'IA per la scoperta di farmaci e la biodefense.
Lunai Bioworks (Nasdaq:LNAI) anunció que ha recuperado el cumplimiento con el requisito mínimo de precio de oferta de Nasdaq bajo Listing Rule 5550(a)(2). El personal de Nasdaq había notificado a la empresa el 14 de abril de 2025 que las acciones comunes de LNAI no mantenían un precio mínimo de $1,00 durante los 30 días hábiles anteriores. El personal determinó que el precio de cierre estaba en o por encima de $1,00 durante 11 días hábiles consecutivos desde el 30 de septiembre de 2025 hasta el 14 de octubre de 2025, restaurando el cumplimiento y dejando a la empresa elegible para permanecer listada en The Nasdaq Capital Market. La dirección dijo que el hito apoya su enfoque en avanzar una plataforma impulsada por IA para el descubrimiento de fármacos y la biodefensa.
Lunai Bioworks (Nasdaq:LNAI)는 Nasdaq의 최소 호가 요건 Listing Rule 5550(a)(2)을 다시 충족하게 되었다고 발표했습니다. Nasdaq 직원은 2025년 4월 14일에 LNAI의 보통주가 직전 30영업일 동안 1.00달러의 최저 호가를 유지하지 못했다고 회사에 통지했습니다. 직원은 2025년 9월 30일부터 2025년 10월 14일 사이의 연속 11영업일 동안 종가가 1.00달러 이상였다고 판단하여 규정 준수를 회복하고 회사가 Nasdaq Capital Market에 상장될 수 있음을 남겨두었습니다. 경영진은 이 이정표가 의약품 발견 및 생물방어를 위한 AI 기반 플랫폼 개발에 주력하는 것을 뒷받침한다고 말했습니다.
Lunai Bioworks (Nasdaq:LNAI) a annoncé avoir renoué avec la conformité à l'exigence de cours boursier minimum de Nasdaq sous Listing Rule 5550(a)(2). Le personnel de Nasdaq avait informé l'entreprise le 14 avril 2025 que l'action ordinaire de LNAI n'avait pas maintenu un cours minimum de 1,00 $ au cours des 30 jours ouvrables précédents. Le personnel a déterminé que le cours de clôture était égal ou supérieur à 1,00 $ pendant 11 jours ouvrables consécutifs du 30 septembre 2025 au 14 octobre 2025, rétablissant la conformité et laissant l'entreprise éligible à rester cotée sur The Nasdaq Capital Market. La direction a déclaré que cette étape confirme son objectif de développer une plateforme alimentée par l'IA pour la découverte de médicaments et la biodefense.
Lunai Bioworks (Nasdaq:LNAI) hat bekannt gegeben, dass es die Einhaltung der Nasdaq-Anforderung für den Mindest-Bid-Price gemäß Listing Rule 5550(a)(2) wiedererlangt hat. Das Nasdaq-Personal hatte dem Unternehmen am 14. April 2025 mitgeteilt, dass der Stammaktienkurs von LNAI in den vorherigen 30 Bankarbeitstagen keinen Mindestkurs von 1,00 USD erreicht hatte. Das Personal stellte fest, dass der Schlusskurs in 11 aufeinanderfolgenden Handelstagen vom 30. September 2025 bis zum 14. Oktober 2025 auf oder über 1,00 USD lag, wodurch die Einhaltung wiederhergestellt wurde und das Unternehmen berechtigt blieb, an der Nasdaq Capital Market gelistet zu bleiben. Das Management sagte, dass dieser Meilenstein seine Fokussierung auf die Weiterentwicklung einer KI-basierten Plattform für die Arzneimittelentdeckung und Biodefense unterstützt.
Lunai Bioworks (Nasdaq:LNAI) أعلنت أنها استأنفت الامتثال لمتطلب سعر العرض الأدنى في ناسداك بموجب Listing Rule 5550(a)(2). كان موظفو ناسداك قد أبلغوا الشركة في 14 أبريل 2025 أن سعر سهم لواناي العادي لم يحافظ على الحد الأدنى البالغ 1.00 دولار على مدى الـ 30 يوماً عملياً السابقة. وقرر الموظفون أن سعر الإغلاق كان عند أو فوق 1.00 دولار لمدة 11 يوماً عملياً متتالياً من 30 سبتمبر 2025 حتى 14 أكتوبر 2025، مما استعاد الامتثال وترك الشركة مؤهلة للبقاء مدرجة في Nasdaq Capital Market. وقالت الإدارة أن هذا الإنجاز يدعم تركيزها على تطوير منصة مدعومة بالذكاء الاصطناعي لاكتشاف الأدوية والدفاع البيولوجي.
Lunai Bioworks (Nasdaq:LNAI) 宣布已重新符合纳斯达克最低出价要求，符合 Listing Rule 5550(a)(2)。纳斯达克工作人员曾在 2025年4月14日 通知公司，LNAI的普通股在前30个交易日未能维持1.00美元的最低出价。工作人员确定在 2025年9月30日至2025年10月14日的11个连续交易日的收盘价达到或高于1.00美元，从而恢复合规，使公司有资格继续在纳斯达克资本市场上市。管理层表示，这一里程碑支持其以AI驱动的平台推进药物发现与生物防务的愿景。
- Regained Nasdaq compliance after 11 consecutive business days at or above $1.00
- Remains eligible for continued listing on The Nasdaq Capital Market
- Notified on April 14, 2025 of prior failure to maintain $1.00 minimum bid
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.
On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of
"This compliance milestone reflects our commitment to strategic execution and shareholder value during a transformative period for Lunai Bioworks," said David Weinstein, Chief Executive Officer. "We remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense."
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
http://www.lunaibioworks.com/
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
When did Lunai Bioworks (LNAI) regain Nasdaq minimum bid price compliance?
What Nasdaq rule did LNAI fail to meet earlier in 2025?
Does Lunai Bioworks remain listed on Nasdaq after regaining compliance?
How long was the compliance run that restored LNAI's Nasdaq status?
What period triggered Nasdaq's noncompliance notice for LNAI in April 2025?
